Breast Cancer Clinical Trial
Official title:
A Physical Activity Intervention to Prevent Weight Gain in Breast Cancer Patients
RATIONALE: Physical activity may prevent or reduce weight gain in women receiving
chemotherapy for early stage breast cancer.
PURPOSE: This randomized phase I/II trial is studying physical activity to see how well it
works compared with usual care to prevent or reduce weight gain in women with stage I or
stage II breast cancer undergoing chemotherapy.
OBJECTIVES:
Primary
- Determine the feasibility for conducting a clinical trial that uses a 6-month physical
activity intervention initiated within 45 days after surgery for early-stage breast
cancer and prior to initiation of adjuvant chemotherapy, hormonal therapy, and/or
radiotherapy. (phase I)
- Determine if participation in a 6-month physical activity intervention initiated within
45 days after surgery for early-stage breast cancer decreases weight gain in patients
treated with adjuvant chemotherapy. (phase II)
- Determine if participation in a 6-month physical activity intervention initiated within
45 days after surgery for early-stage breast cancer differentially affects weight
change in women who are premenopausal compared to those who are postmenopausal at
diagnosis. (phase II)
Secondary
- Determine if participation in a 6-month physical activity intervention initiated within
45 days after surgery for early-stage breast cancer decreases gains in adiposity in
patients treated with adjuvant chemotherapy. (phase II)
- Determine if participation in a 6-month physical activity intervention initiated within
45 days after surgery for early-stage breast cancer differentially affects change in
adiposity among women who are premenopausal compared to those who are postmenopausal at
diagnosis. (phase II)
- Determine if participation in a 6-month physical activity intervention initiated within
45 days after surgery for early-stage breast cancer decreases the frequency of
depressive symptomology and improves quality of life among patients treated with
adjuvant chemotherapy. (phase II)
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
participating site and menopausal status (premenopausal vs postmenopausal). Patients are
randomized to 1 of 2 intervention arms.
- Arm I (exercise and usual care): Patients receive usual care and are enrolled in an
exercise and weight control program at Curves® fitness center. The Curves® program,
which begins during the third week of study, uses aerobic activity and resistance
training to reduce weight and increase strength and fitness. Patients exercise a
minimum of 3 times per week, approximately 30 minutes every time, for up to 6 months in
the absence of disease progression or unacceptable toxicity. Patients' physical
activity is measured at baseline and at the 3- and 6-month follow-up visits.
Patients also undergo behavior modification counseling with a study nurse to help them
overcome the specific barriers to adhering to the recommended exercise routine. Counseling
sessions are conducted every 2 to 3 weeks during chemotherapy and at least monthly after
completion of chemotherapy for up to 6 months, starting within 2 weeks after randomization
and prior to initiation of the Curves® intervention.
- Arm II (control: usual care alone): Patients receive usual care and general advice on
coping with their breast cancer treatment for up to 6 months in the absence of disease
progression or unacceptable toxicity. Patients receive no counseling or recommendations
concerning emotional and practical barriers encountered during breast cancer treatment.
Dietary information is obtained from patients by telephone during three 24-hour dietary
recalls performed within 2 weeks of baseline and at the 3-month and 6-month follow-up visits
to estimate total energy intake throughout the study. Patients complete questionnaires at
baseline and periodically during study assessing demographic characteristics and established
breast cancer risk factors, medical history, and health changes. Weight, adiposity as
measured by waist circumference, quality of life, and depressive symptomology are assessed
at baseline and at the 3- and 6-month follow-up visits.
After completion of the study intervention, patients are followed for up to 6 months.
;
Allocation: Randomized, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |